A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

Key Inclusion Criteria

• PAH belonging to one of the subgroups:

1. I/HPAH, PAH-CTD,

2. PAH due to drugs and/or toxins/chemicals (having been in the care of the investigator for at least one year with no relapses of drug or toxin/chemical abuse),

3. HIV associated or

4. PAH due to repaired congenital heart disease (at least 1 year since repair)

• World Health Organization (WHO) Functional Class II, III or IV symptoms

• Stable concomitant background therapy of at least one PAH approved medications

• Able to walk a distance of at least 100 m but no more than 475 m during the Screening 6-minute walk tests.

Key Exclusion Criteria

• Pulmonary hypertension (PH) belonging to Groups 2 to 5

• A history of left-sided heart disease

• Pregnant or breast-feeding females

Additional criteria may apply, per protocol